Pola Chemical Industries, Inc.

Pola Chemical Industries Inc., Japan

Kenichi Kishii

Takayuki Namiki

Naoki Hiyama

Masashi Tamai

Satoshi Ichinomiya

Makoto Kimura

Masayuki Yuasa

Yukio Kawazu

Masaki Mitani

Masato Inazu

Toshihiro Morimoto

Takako Takakuwa

Mayumi Sugio

Mariko Harada

Tomoaki Yahiro

Norio Funayama

Kyoko Taneda

Takeshi Yamamoto

Masayuki Yanagi

Nobuyuki Kawakatsu

Yuji Yoshiko

Kazunori Harada

Michihiko Tsujitani

Yoshiaki Motoki

Ichiro Matsuo

Kyoko Yamasaki

Mariko Onoda

Biphenyl derivatives represented by the following formula (1): wherein Rrepresents a Calkyl group, Rrepresents a substituted or unsubstituted aromatic hydrocarbon, or cycloalkyl group, Rrepresents a tetrazolyl group, &#x2014;NHCOCF, &#x2014;NHSOCFor &#x2014;SONHCONHRin which Rrepresents a substituted or unsubstituted aromatic hydrocarbon group, and Z represents a single bond, a Calkylene group or &#x2014;SONH&#x2014;, and salts thereof; and ACAT inhibitors and medicines containing them as active ingredients. The compounds according to the present invention possess excellent ACAT inhibitory activities, and are useful as preventives and/or therapeutics for diseases cased by the enhancement of ACAT activity, for example, hypercholesterolemia, atherosclerosis and the like.

Biphenyl derivatives

The invention relates to compounds represented by the following general formula (1): ##STR1## wherein R.sup.1 represents an alkyl group, R.sup.2 represents an amino group, alkyl group or the like, and R.sup.3 represents a nitro group, amino group, heterocyclic group, alkylsulfonylamino group or the like, or salts thereof, medicines comprising such a compound, a preparation process of the compounds, and intermediates useful for preparation thereof. The compounds (1) are useful for the prevention and treatment of a respiratory disease.

Pyrrolopyrazolopyrimidine compound and medicine comprising the same as

Dopamine re-uptake inhibitor

Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidine derivatives are disclosed. The compounds are represented by the formula (I), ##STR1## wherein R.sub.1 and R.sub.2 individually represent a hydrogen atom, a linear or branched alkyl group which may have a substituent, a cycloalkyl or phenyl group which may have a substituent, or a heterocyclic group which may have a substituent, and R.sub.3 is a hydrogen atom or a cyano group. The compounds have excellent circulatory disease curing activities as well as bronchodilation activities.

Pyrrolo(3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine

Growing community of inventors

Yokohama, Japan

Kenichi Kishii